181 related articles for article (PubMed ID: 14623528)
1. Advanced breast cancer updates on anastrozole versus tamoxifen.
Nabholtz JM;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):321-5. PubMed ID: 14623528
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
3. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
[TBL] [Abstract][Full Text] [Related]
6. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Nabholtz JM; Bonneterre J; Buzdar A; Robertson JF; Thürlimann B
Eur J Cancer; 2003 Aug; 39(12):1684-9. PubMed ID: 12888362
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
10. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
Eur J Cancer; 2000 Sep; 36 Suppl 4():S84-5. PubMed ID: 11056332
[TBL] [Abstract][Full Text] [Related]
11. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
[TBL] [Abstract][Full Text] [Related]
13. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
15. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Bonneterre J; Buzdar A; Nabholtz JM; Robertson JF; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M; ;
Cancer; 2001 Nov; 92(9):2247-58. PubMed ID: 11745278
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
19. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
